ArticleNanoscale advances2026
Engineered etoposide-prednisolone co-nanocrystals for synergistic antitumor efficacy enhancement.
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present work involves the development of new organic crystalline nanomedicines, namely, co-nanocrystals (co-NCs), that combine a chemotherapeutic agent with an anti-inflammatory active pharmaceutical ingredient (API), both in their nanocrystalline forms. These mixed systems were formulated to improve their anticancer efficiency. For this purpose, formulations composed of etoposide (ETO) and prednisolone (PRD) NCs were prepared. The co-formulations were optimized with the stabilizing agent poloxamer P407. The average size obtained was 191.9 ± 6.5 nm with a polydispersity index of 0.28 ± 0.09 and a zeta potential of -5.0 ± 0.7 mV for the fresh formulations. The drug loading was determined to be at 71.9% ± 0.6% for PRD and 84.1% ± 3.9% for ETO. The obtained co-NCs presented a long-term stability of at least 70 days after storage at 4 °C. Dialysis experiments showed that both APIs were released from the co-formulations following 1st-order kinetics. In addition, the NCs exhibited stronger antitumoral activities
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.